Evidence map›Paper›PMID 41946677›Full record

ArticleMicrosystems & nanoengineering2026

PEGylated Cu-doped WS

Dan Li, Chang Wen, Han Wu, Xiaobin Li, Xiaopeng Zhang, Wenbo Li, Yu Lei, Juan Li, Can Yang Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dan Li *Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, P. R. China.
Chang Wen *Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, P. R. China.
Han WuInstitute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, P. R. China.
Xiaobin LiInstitute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, P. R. China.
Xiaopeng ZhangInstitute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, P. R. China.
Wenbo LiInstitute of Materials Research, Center of Double Helix, Shenzhen International Graduate School, Tsinghua University, Shenzhen, P. R. China.
Yu LeiInstitute of Materials Research, Center of Double Helix, Shenzhen International Graduate School, Tsinghua University, Shenzhen, P. R. China.
Juan LiEnergy and Transportation Domain, Beijing Institute of Technology, Zhuhai, P. R. China.
Can Yang ZhangInstitute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, P. R. China. zhang.cy@sz.tsinghua.edu.cn.ORCID http://orcid.org/0000-0002-6975-5781

Funding

National Natural Science Foundation of China (National Science Foundation of China) 22278242
6 · The paper itself

Abstract

The existing clinical approaches for breast cancer treatment still face many major issues, including poor therapeutic efficacy and high side effects. To address these challenges, we developed a folic acid-functionalized PEGylated WS

Identifiers

PMID41946677
PMCPMC13057255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.